ANGLE – 68p

28 February – Parsortix product launch

The specialist medical technology group ANGLE has announced the launch of its Parsortix non-invasive cancer diagnostic product for the research market.  To accelerate deployment of the Parsortix system, which can identify and capture tumour cells in the blood, ANGLE is in the process of placing machines on loan with a limited number of key users worldwide.  The research work undertaken by these users can be used to add to the data already generated by ANGLE and will help the company in its submissions for FDA approval and CF marking.  This is another important milestone in the group’s development as it moves towards commercialisation of the product.  Although the shares have moved up on the news there could be much further to go and they are a BUY.

cityconfidential © 2019 | T&Cs | Privacy | Wealth Warning